Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

Adv Drug Deliv Rev. 2020:156:214-235. doi: 10.1016/j.addr.2020.06.024. Epub 2020 Jun 27.

Abstract

Viral nanoparticles (VNPs) encompass a diverse array of naturally occurring nanomaterials derived from plant viruses, bacteriophages, and mammalian viruses. The application and development of VNPs and their genome-free versions, the virus-like particles (VLPs), for nanomedicine is a rapidly growing. VLPs can encapsulate a wide range of active ingredients as well as be genetically or chemically conjugated to targeting ligands to achieve tissue specificity. VLPs are manufactured through scalable fermentation or molecular farming, and the materials are biocompatible and biodegradable. These properties have led to a wide range of applications, including cancer therapies, immunotherapies, vaccines, antimicrobial therapies, cardiovascular therapies, gene therapies, as well as imaging and theranostics. The use of VLPs as drug delivery agents is evolving, and sufficient research must continuously be undertaken to translate these therapies to the clinic. This review highlights some of the novel research efforts currently underway in the VNP drug delivery field in achieving this greater goal.

Keywords: Bacteriophages; Cancer; Chemotherapy; Contrast agents; Drug delivery systems; Infectious disease; Plant viruses; Theranostics; Vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Diagnostic Imaging / methods*
  • Drug Delivery Systems*
  • Humans
  • Immunotherapy / methods*
  • Theranostic Nanomedicine / methods*
  • Vaccines / administration & dosage
  • Viruses*

Substances

  • Vaccines